Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup

Rordorf T., Hassan A. A., Azim H., Alexandru E., ER O., Gokmen E., ...Daha Fazla

BREAST, cilt.23, sa.5, ss.511-525, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 23 Sayı: 5
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.breast.2014.05.023
  • Dergi Adı: BREAST
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.511-525
  • Anahtar Kelimeler: Metastatic breast cancer, Skeletal-related events, Bone metastases, Radiotherapy, Bisphosphonates, Denosumab, BODY RADIATION-THERAPY, VERTEBRAL COMPRESSION FRACTURES, PALLIATIVE RADIOTHERAPY TRIALS, POSITRON-EMISSION-TOMOGRAPHY, QUALITY-OF-LIFE, PHASE-II TRIAL, DELTA T-CELLS, ZOLEDRONIC ACID, SKELETAL COMPLICATIONS, RANDOMIZED-TRIAL
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Bone is the most common site of distant metastases in breast cancer that can cause severe and debilitating skeletal related events (SRE) including hypercalcemia of malignancy, pathologic fracture, spinal cord compression and the need for palliative radiation therapy or surgery to the bone. SRE are associated with substantial pain and morbidity leading to frequent hospitalization, impaired quality of life and poor prognosis. The past 25 years of research on the pathophysiology of bone metastases led to the development of highly effective treatment options to delay or prevent osseous metastases and SRE. Management of bone metastases has become an integral part of cancer treatment requiring expertise of multidisciplinary teams of medical and radiation oncologists, surgeons and radiologists in order to find an optimal treatment for each individual patient.